Dr. Sarah Headland leads Biology at Sound Biologics, overseeing drug development programs in neurology, autoimmunity, and oncology. She manages a team advancing multi-specific antibodies and brain-shuttle technologies, with responsibility for IND-enabling packages and external collaborations.
Previously, Dr. Headland served as Associate Director of Myeloid Biology at Immunai and held scientific leadership roles at Spring Discovery, Alector, and Genentech. Her work has contributed to multiple patents and publications in Science Translational Medicine, Cell Reports, and other leading journals.
She earned her Ph.D. in Biochemical Pharmacology from Queen Mary University of London and completed a postdoctoral fellowship at UC San Francisco as an Arthritis Research UK Foundation Fellow.
